The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties

Robert M Bennett, Ronald Friend, Kim D Jones, Rachel Ward, Bobby K Han, Rebecca L Ross, Robert M Bennett, Ronald Friend, Kim D Jones, Rachel Ward, Bobby K Han, Rebecca L Ross

Abstract

Introduction: The Fibromyalgia Impact Questionnaire (FIQ) is a commonly used instrument in the evaluation of fibromyalgia (FM) patients. Over the last 18 years, since the publication of the original FIQ, several deficiencies have become apparent and the cumbersome scoring algorithm has been a barrier to widespread clinical use. The aim of this paper is to describe and validate a revised version of the FIQ: the FIQR.

Methods: The FIQR was developed in response to known deficiencies of the FIQ with the help of a patient focus group. The FIQR has the same 3 domains as the FIQ (that is, function, overall impact and symptoms). It differs from the FIQ in having modified function questions and the inclusion of questions on memory, tenderness, balance and environmental sensitivity. All questions are graded on a 0-10 numeric scale. The FIQR was administered online and the results were compared to the same patient's online responses to the 36-Item Short Form Health Survey (SF-36) and the original FIQ.

Results: The FIQR was completed online by 202 FM patients, 51 rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) patients (31 RA and 20 SLE), 11 patients with major depressive disorder (MDD) and 213 healthy controls (HC). The mean total FIQR score was 56.6 +/- 19.9 compared to a total FIQ score of 60.6 +/- 17.8 (P < 0.03). The total scores of the FIQR and FIQ were closely correlated (r = 0.88, P < 0.001). Each of the 3 domains of the FIQR correlated well with the 3 related FIQ domains (r = 0.69 to 0.88, P < 0.01). The FIQR showed good correlation with comparable domains in the SF-36, with a multiple regression analysis showing that the three FIQR domain scores predicted the 8 SF-36 subscale scores. The FIQR had good discriminant ability between FM and the 3 other groups; total FIQR scores were HC (12.1 +/- 11.6), RA/SLE (28.6 +/- 21.2) and MDD (17.3 +/- 11.8). The patient completion time was 1.3 minutes; scoring took about 1 minute.

Conclusions: The FIQR is an updated version of the FIQ that has good psychometric properties, can be completed in less than 2 minutes and is easy to score. It has scoring characteristics comparable to the original FIQ, making it possible to compare past FIQ results with future FIQR results.

Figures

Figure 1
Figure 1
Histograms of FIQ and FIQR showing distributions of total scores. (a) The distribution profile of the total Revised Fibromyalgia Impact Questionnaire (FIQR) scores in 202 fibromyalgia (FM) patients. (b) The distribution profile of the total Fibromyalgia Impact Questionnaire (FIQ) scores. There is a slight negative skewness for both distributions. The FIQR Shapiro-Wilk skewness coefficient (W) is 0.978, and the FIQ Shapiro-Wilk skewness coefficient (W) is 0.980.
Figure 2
Figure 2
A scatterplot of the total score for the Revised Fibromyalgia Impact Questionnaire (FIQR) and the Fibromyalgia Impact Questionnaire (FIQ) on all 202 fibromyalgia subjects (r = 0.88, P < 0.001).
Figure 3
Figure 3
The total Revised Fibromyalgia Impact Questionnaire (FIQR) scores of the 202 fibromyalgia (FM) patients compared with the scores for the 213 healthy controls, 51 patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE), and 11 patients with major depression. *Note: a concomitant diagnosis of FM was an exclusion criterion for inclusion of RA/SLE and major depressive disorder (MDD) subjects. SE, standard error.
Figure 4
Figure 4
A plot of the mean scores for the four new symptoms added to the Revised Fibromyalgia Impact Questionnaire (memory, tenderness, balance, and environmental sensitivity) against each of the four groups: fibromyalgia (FM), rheumatoid arthritis/systemic lupus erythematosus (RA/SLE), healthy, and major depressive disorder (MDD).

References

    1. Burckhardt CS, Clark BD, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol. 1991;18:728–733.
    1. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol. 2005;23:S154–S162.
    1. Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol. 2000;27:2683–2691.
    1. Offenbacher M, Cieza A, Brockow T, Amann E, Kollerits B, Stucki G. Are the contents of treatment outcomes in fibromyalgia trials represented in the International Classification Of Functioning, Disability, and Health? Clin J Pain. 2007;23:691–701. doi: 10.1097/AJP.0b013e318148b93d.
    1. Prodinger B, Cieza A, Williams DA, Mease P, Boonen A, Kerschan-Schindl K, Fialka-Moser V, Smolen J, Stucki G, Machold K, Stamm T. Measuring health in patients with fibromyalgia: content comparison of questionnaires based on the International Classification of Functioning, Disability and Health. Arthritis Rheum. 2008;59:650–658. doi: 10.1002/art.23559.
    1. Iversen MD. Fibromyalgia: The Fibromyalgia Impact Questionnaire (FIQ) Arthritis Rheum. 2003;49:S210–S213. doi: 10.1002/art.11397.
    1. Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin S, Perera P, Russell IJ, Simon L, Spaeth M, Williams D, Crofford L. Fibromyalgia syndrome. J Rheumatol. 2007;34:1415–1425.
    1. World Health Organization . International Classification of Functioning, Disability and Health (ICF) Geneva: World Health Organization; 2001.
    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27. doi: 10.1186/1471-2474-8-27.
    1. Hauser W, Zimmer C, Felde E, Kollner V. What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association. Schmerz. 2008;22:176–183. doi: 10.1007/s00482-007-0602-z.
    1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam A, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon R. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172. doi: 10.1002/art.1780330203.
    1. Ware JR, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. Hoffman DL, Dukes EM. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract. 2008;62:115–126.
    1. Birtane M, Uzunca K, Taştekin N, Tuna H. The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis by using SF-36 Health Survey. Clin Rheumatol. 2007;26:679–684. doi: 10.1007/s10067-006-0359-2.
    1. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum. 2005;53:519–527. doi: 10.1002/art.21319.
    1. Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, Abetz L, Martin SA. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient delphi exercises. Arthritis Rheum. 2008;59:952–960. doi: 10.1002/art.23826.
    1. Jones KD, Horak FB, Winters-Stone K, Irvine JM, Bennett RM. Fibromyalgia is associated with impaired balance and falls. J Clin Rheumatol. 2009;15:16–21. doi: 10.1097/RHU.0b013e318190f991.
    1. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry. 2003;182:214–220. doi: 10.1192/bjp.182.3.214.
    1. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH, Charney DS, Bremner JD. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry. 2004;56:101–112. doi: 10.1016/j.biopsych.2004.04.002.
    1. Hieblinger R, Coenen M, Stucki G, Winkelmann A, Cieza A. Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for chronic widespread pain from the perspective of fibromyalgia patients. Arthritis Res Ther. 2009;11:R67. doi: 10.1186/ar2696.
    1. Pincus T, Bergman M, Sokka T, Roth J, Swearingen C, Yazici Y. Visual analog scales in formats other than a 10 centimeter horizontal line to assess pain and other clinical data. J Rheumatol. 2008;35:1550–1558. doi: 10.3899/jrheum.080182.
    1. Couper MP, Tourangeau R, Conrad FG, Singer E. Evaluating the effectiveness of visual analog scales: a Web Experiment. Social Science Computer Review. 2006;24:227–245. doi: 10.1177/0894439305281503.
    1. Hollen PJ, Gralla RJ, Kris MG, McCoy S, Donaldson GW, Moinpour CM. A comparison of visual analogue and numerical rating scale formats for the Lung Cancer Symptom Scale (LCSS): does format affect patient ratings of symptoms and quality of life? Qual Life Res. 2005;14:837–847. doi: 10.1007/s11136-004-0833-8.
    1. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, IMMPACT et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19. doi: 10.1016/j.pain.2004.09.012.
    1. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36:1304–1311. doi: 10.3899/jrheum.081090.

Source: PubMed

3
S'abonner